2-{2-[3-(Pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl}pyridine: A highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 22, 2004, Pages 5473-5476

  Huang, Dehua ^a   Poon, Steve F ^a   Chapman, Deborah F ^a   Chung, Janice ^a   Cramer, Merryl ^a   Reger, Thomas S ^a   Roppe, Jeffrey R ^a   Tehrani, Lida ^a   Cosford, Nicholas D P ^a   Smith, Nicholas D ^a  

^a GENERAL ATOMICS   (United States)

Author keywords

Antagonist; Metabotropic glutamate; Tetrazole

Indexed keywords

2 [2 [3 (PYRIDIN 3 YLOXY)PHENYL] 2H TETRAZOL 5 YL]PYRIDINE; 3 (5 PYRIDIN 2 YL 2H TETRAZOL 2 YL)BENZONITRILE; BENZONITRILE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; PENTETRAZOLE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; MONKEY; NONHUMAN; RECEPTOR OCCUPANCY; STRUCTURE ACTIVITY RELATION;

EID: 5144220159     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.09.012     Document Type: Article

References (22)

1. G.J. Siegel, B.W. Aganoff, R.W. Albers, S.K. Fisher, and M.D. Uhler Basic Neurochemistry: Molecular, Cellular and Medicinal Aspects 6th ed. 1999 Lippincott, Williams and Wilkins Philadelphia, PA
2. J.-P. Pin, and F. Acher Curr. Drug Targets: CNS Neurol. Disord. 1 2002 297 317
3. J. Brodkin, C. Busse, S.J. Sukoff, and M.A. Varney Pharmacol., Biochem. Behav. 73 2002 359 366
4. W.P.J.M. Spooren, A. Vassout, H.C. Neijt, R. Kuhn, F. Gasparini, S. Roux, R.D. Porsolt, and C. Gentsch J. Pharmacol. Exp. Ther. 295 2000 1267 1275
5. B. Schulz, M. Fendt, F. Gasparini, K. Lingenhöhl, R. Kuhn, and M. Koch Neuropharmacology 41 2001 1 7
6. A. Klodzinska, E. Tatarczynska, E. Chojnacka-Wojcik, and A. Pilc Pol. J. Pharmacol. 52 2000 463 466
7. W.P.J.M. Spooren, P. Schoeffter, F. Gasparini, R. Kuhn, and C. Gentsch Eur. J. Pharmacol. 435 2002 161 170
8. E. Tatarczynska, A. Klodzinska, E. Chojnacka-Wojcik, A. Palucha, F. Gasparini, R. Kuhn, and A. Pilc Br. J. Pharmacol. 132 2001 1423 1430
9. M.A. Varney, and R.W.I. Gereau Curr. Drug Targets: CNS Neurol. Disord. 1 2002 283 296
10. C. Chiamulera, M.P. Epping-Jordan, A. Zocchi, C. Marcon, C. Cottiny, S. Tacconi, M. Corsi, F. Orzi, and F. Conquet Nat. Neurosci. 4 2001 873 874
11. K.M. Huber, S.M. Gallagher, S.T. Warren, and M.F. Bear Proc. Nat. Acad. Sci. 99 2002 7746
12. N.D.P. Cosford, L. Tehrani, J. Roppe, E. Schweiger, and N.D. Smith J. Med. Chem. 46 2003 204 206
13. J. Roppe, N.D. Smith, D. Huang, L. Tehrani, B. Wang, J. Anderson, J. Brodkin, J. Chung, X. Jiang, C. King, C. King, B. Munoz, M.A. Varney, P. Prasit, and N.D.P. Cosford J. Med. Chem. 47 2004 4645 4648
14. 50 > 10 μM)
15. Solubility of HCl salt of 2 is 1.6 mg/mL in PEG 400/water (V/V = 1:1). While the HCl salt of 9 is 36 mg/mL in PEG/400 water (V/V = 1:1)
16. S. Ito, Y. Tanaka, and K. Kakehi Chem. Lett. 10 1973 1071 1072
17. D.W. Old, M.C. Harris, and S.L. Buchwald Org. Lett. 2 2000 1403 1406
18. M.A. Ali, and S.L. Buchwald J. Org. Chem. 66 2001 2560 2565
19. 2+ flux assay
20. L.P. Daggett, A.I. Sacaan, M. Akong, S.P. Rao, S.D. Hess, C. Liaw, A. Urrutia, C. Jachec, S.B. Ellis, J. Dreeseen, T. Knopfel, C.M. Testa, G.B. Landwehrmeyer, A.B. Young, M. Varney, E.C. Johnson, and G. Velicelebni Neuropharmacology 34 1995 871 886
21. N.D.P. Cosford, J. Roppe, L. Tehrani, T.J. Seiders, E.J. Schweiger, S. Chaudary, S. Rao, and M.A. Varney Bioorg. Med. Chem. Lett. 13 2003 351 354
22. J.J. Anderson, M.J. Bradbury, D.R. Giracello, D.F. Chapman, G. Holtz, J. Roppe, C. King, N.D.P. Cosford, and M.A. Varney Eur. J. Pharmacol. 473 2003 35 40